Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an announcement.
CR Double-Crane, a subsidiary of China Resources Pharmaceutical Group Ltd., reported a decrease in total assets and net profit for the year ending December 31, 2024, compared to the previous year. Despite a slight decline in revenue and net profit, the company saw a significant increase in net profit excluding extraordinary gains or losses, and proposed a cash dividend distribution to shareholders, reflecting a strategic focus on shareholder returns.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company, through its subsidiary CR Double-Crane, is primarily engaged in the Chinese market, with shares listed on the Shanghai Stock Exchange.
YTD Price Performance: -5.88%
Average Trading Volume: 2,135
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €4.2B
See more data about 3320 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue